Biotechnology - Sanofi

Filter

Current filters:

Sanofi

Popular Filters

55 to 79 of 2321 results

Xenon and Genentech establish new pain discovery collaboration

26-03-2014

Privately-held US biotech firm Xenon Pharmaceuticals has established a new collaboration with Swiss drug…

BiotechnologyGenentechLicensingNeurologicalResearchRocheXenon Pharmaceuticals

Adaptimmune announces appointment of James Noble as Chief Executive Officer

Adaptimmune announces appointment of James Noble as Chief Executive Officer

26-03-2014

Adaptimmune, a biotech company focused on the use of engineered T cells to treat cancer, has announced…

AdaptimmuneBiotechnologyBoardroomImmunocoreUK

Merck promotes internal top managers to head Merck Millipore and Consumer Health Divisions

Merck promotes internal top managers to head Merck Millipore and Consumer Health Divisions

26-03-2014

German pharma and chemical major Merck KGaA has announced the promotion of three distinguished internal…

AllergopharmaBiotechnologyBoardroomGermanyMerck KGaAPharmaceutical

Angle appointments new Scientific Adviser

Angle appointments new Scientific Adviser

26-03-2014

Angle (AIM:AGL), the specialist medtech company, has appointed Clive Stanway as a Scientific Adviser…

AngleBiotechnologyBoardroomCancer Research TechnologyOncologyUK

EU approval for Cometriq in medullary thyroid carcinoma

EU approval for Cometriq in medullary thyroid carcinoma

25-03-2014

The European Commission has approved Cometriq (cabozantinib), a drug for the treatment of adult patients…

BiotechnologyCometriqEuropeExelixisOncologyRegulationSwedish Orphan Biovitrum

AstraZeneca unit debuts new open innovation platform for partnering programs

25-03-2014

Anglo-Swedish drug major AstraZeneca’s IMED Biotech unit has launched a dedicated web site to support…

AstraZenecaBiotechnologyResearch

NICE final guidance again rejects Sanofi’s Zaltrap for colorectal cancer

25-03-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE), today issued final guidance…

Northern EuropeOncologyPharmaceuticalPricingRegulationSanofiUKZaltrap

Positive Ph III results with oral Otezla in skin, nail and scalp of patients with plaque psoriasis

24-03-2014

US biotech firm Celgene has released positive new research findings on Otezla (apremilast), an oral,…

apremilastBiotechnologyCelgeneDermatologicalsOtezlaResearch

US lawmakers question price of Gilead’s Sovaldi

US lawmakers question price of Gilead’s Sovaldi

24-03-2014

Three leading US Congressmen have written to John Martin, chief executive of US biotech firm Gilead Sciences,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPoliticsPricingRegulationSovaldiUSA

US FDA clears Xolair for chronic idiopathic urticaria

23-03-2014

Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

US FDA eases clinical hold on Geron’s imetelstat

US FDA eases clinical hold on Geron’s imetelstat

21-03-2014

There was a touch of good news yesterday for Geron Corp, after the US Food and Drug Administrated partially…

BiotechnologyGeron CorpimetelstatNorth AmericaOncologyRegulationResearchUSA

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

20-03-2014

US biotech company Emmaus Life Sciences, which focuses on orphan diseases, has announced preliminary…

BiotechnologyHematologyResearchUSA

BioAlliance Pharma licenses Sitavig to Innocutis in North America

19-03-2014

French drug developer BioAlliance Pharma has executed a licensing accord with the USA’s Innocutis Holdings…

Anti-viralsBioAlliance PharmaBiotechnologyInnocutis HoldingsLicensingNorth AmericaSitavig

Promising mid-stage results for Prosensa’s drisapersen in DMD boys

19-03-2014

Shares of Dutch biotech firm Prosensa Holding rose 3.85% to $7.02 after the firm reported encouraging…

BiotechnologydrisapersenGlaxoSmithKlineProsensaRare diseasesResearch

UK budget unveils £55 million Cell Therapy Manufacturing Centre

UK budget unveils £55 million Cell Therapy Manufacturing Centre

19-03-2014

The UK’s annual budget speech by Chancellor of the Exchequer George Osborne today included the announcement…

BiotechnologyFinancialPoliticsResearchUK

Pan-European survey calls for a shift in policy for biosimilars

Pan-European survey calls for a shift in policy for biosimilars

19-03-2014

This week, the Alliance for Safe Biologic Medicines (ASBM) disclosed the results of a survey of 470 European…

BiosimilarsBiotechnologyEuropeHealthcareRegulation

Medigene signs collaboration with Falk Pharma for RhuDex

Medigene signs collaboration with Falk Pharma for RhuDex

19-03-2014

German biotechnology company Medigene has signed an exclusive global license agreement with drugmaker…

BiotechnologyDr Falk PharmaGastro-intestinalsGermanyLicensingMedigeneNephrology and Hepatology

Celgene UK and Ireland appoint Rob Moore as Inflammation and Immunology Business Unit Director

Celgene UK and Ireland appoint Rob Moore as Inflammation and Immunology Business Unit Director

19-03-2014

Celgene UK and Ireland have announced the appointment of Rob Moore as the new Inflammation and Immunology…

BiotechnologyBoardroomCelgeneNorthern EuropeUK

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

19-03-2014

In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline…

ADC TherapeuticsBiotechnologyInterviewsNorthern EuropeOncology

Sanofi Pasteur inks deal with Korea’s SK Chemical on vaccines

Sanofi Pasteur inks deal with Korea’s SK Chemical on vaccines

19-03-2014

In a second collaboration in less than a month, Sanofi Pasteur, the vaccines division of French drug…

Asia-PacificLicensingPharmaceuticalResearchSanofiSanofi PasteurSK ChemicalVaccines

FDA delays approval of Biogen Idec’s MS drug Plegridy

FDA delays approval of Biogen Idec’s MS drug Plegridy

18-03-2014

The US Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for…

Biogen IdecBiotechnologyNeurologicalNorth AmericaPlegridyRegulationUSA

Executive Q&A: Fibrotech's chief executive Darren Kelly

Executive Q&A: Fibrotech's chief executive Darren Kelly

18-03-2014

The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product,…

AustraliaBiotechnologyFibrotechInterviewsNephrology and Hepatology

55 to 79 of 2321 results

Back to top